Drug data · shortage, price, volume

Pindolol tablets: listed 22 months as a shortage, and the generic benchmark price fell 38% since 2021

The FDA has listed this drug as short in the past. The pharmacy benchmark says the generic tablet now costs $0.556 each, against $0.903 in 2014. Availability and price are different measures, so this page shows both over time.

FDA shortage list, 2026-11-05NADAC, November 2026Medicaid SDUDinferred monthno data
  1. The tablet was on the FDA list from March 2020 to December 2021, 22 months, and is not listed now.
  2. 46% of shortage listings since 2014 lasted as long as this one. The median lasts 21 months.
  3. A generic 5 mg tablet costs pharmacies $0.556 on the NADAC benchmark in November 2026, 38% below its 2021 median.
  4. Medicaid paid for 663 tablet prescriptions in Q4 2025, 88% more than in Q4 2021.

Not medical advice. This page reports public records about supply and pharmacy cost. Ask a pharmacist or prescriber about your own medication.

Three clocks on one timeline

Each lane uses the same monthly axis, so you can read across: when the FDA listed the tablet, what pharmacies were paying, and how many Medicaid prescriptions were filled.

on the listinferred across a missing captureno capture or no price$ per tabletprescriptionspreliminary quarter

Swipe the chart sideways to see all 13 years.

Three clocks: FDA shortage list, pharmacy acquisition cost and Medicaid prescriptionsShared monthly timeline. Top lane: months the tablet was on the FDA shortage list. Middle lane: NADAC price per tablet by strength. Bottom lane: Medicaid prescriptions per quarter. 201520162017201820192020202120222023202420252026FDA shortage listtablet, by name2014-04 to 2014-05: no capture of the FDA list for these months2014-09 to 2014-09: no capture of the FDA list for these months2016-02 to 2016-02: no capture of the FDA list for these months2018-10 to 2018-11: no capture of the FDA list for these months2019-02 to 2019-04: no capture of the FDA list for these months2020-03 to 2021-12: on the list (observed)2024-10 to 2025-08: no capture of the FDA list for these monthsfirst listed Mar 2020Pharmacy costNADAC, $ per tabletbold = 5 mg generic$0$0.75$1.5$0.903 in 2014$0.556 nowMedicaid fillsprescriptions per quartertablet2014Q2: 63 prescriptions; unsuppressed state rows only2014Q3: 213 prescriptions; unsuppressed state rows only2014Q4: 330 prescriptions; unsuppressed state rows only2015Q1: 322 prescriptions; unsuppressed state rows only2015Q2: 350 prescriptions; unsuppressed state rows only2015Q3: 467 prescriptions; unsuppressed state rows only2015Q4: 544 prescriptions; unsuppressed state rows only2016Q1: 415 prescriptions; unsuppressed state rows only2016Q2: 249 prescriptions; unsuppressed state rows only2016Q3: 445 prescriptions; unsuppressed state rows only2016Q4: 497 prescriptions; unsuppressed state rows only2017Q1: 466 prescriptions; unsuppressed state rows only2017Q2: 468 prescriptions; unsuppressed state rows only2017Q3: 381 prescriptions; unsuppressed state rows only2017Q4: 426 prescriptions; unsuppressed state rows only2018Q1: 427 prescriptions; unsuppressed state rows only2018Q2: 520 prescriptions; unsuppressed state rows only2018Q3: 534 prescriptions; unsuppressed state rows only2018Q4: 510 prescriptions; unsuppressed state rows only2019Q1: 591 prescriptions; unsuppressed state rows only2019Q2: 589 prescriptions; unsuppressed state rows only2019Q3: 609 prescriptions; unsuppressed state rows only2019Q4: 551 prescriptions; unsuppressed state rows only2020Q1: 252 prescriptions; unsuppressed state rows only2020Q2: 44 prescriptions; unsuppressed state rows only2020Q3: 227 prescriptions; unsuppressed state rows only2020Q4: 388 prescriptions; unsuppressed state rows only2021Q1: 484 prescriptions; unsuppressed state rows only2021Q2: 791 prescriptions; unsuppressed state rows only2021Q3: 512 prescriptions; unsuppressed state rows only2021Q4: 352 prescriptions; unsuppressed state rows only2022Q1: 406 prescriptions; unsuppressed state rows only2022Q2: 495 prescriptions; unsuppressed state rows only2022Q3: 563 prescriptions; unsuppressed state rows only2022Q4: 569 prescriptions; unsuppressed state rows only2023Q1: 704 prescriptions; unsuppressed state rows only2023Q2: 626 prescriptions; unsuppressed state rows only2023Q3: 741 prescriptions; unsuppressed state rows only2023Q4: 782 prescriptions; unsuppressed state rows only2024Q1: 780 prescriptions; unsuppressed state rows only2024Q2: 835 prescriptions; unsuppressed state rows only2024Q3: 860 prescriptions; unsuppressed state rows only2024Q4: 720 prescriptions; unsuppressed state rows only2025Q1: 756 prescriptions; unsuppressed state rows only2025Q2: 688 prescriptions; unsuppressed state rows only2025Q3: 665 prescriptions; unsuppressed state rows only2025Q4: 663 prescriptions; unsuppressed state rows only2026Q1: 644 prescriptions (latest quarter, preliminary: CMS may revise); unsuppressed state rows only8600
Top: months the tablet name was on the FDA list (Wayback captures of the FDA page; the current FDA record says posted 2026-01-30). Middle: NADAC per tablet, one line per strength. Where NADAC reported no price for a strength for more than two months, the line breaks and the gap is hatched: we do not bridge missing prices. Bottom: Medicaid prescriptions per quarter. Medicaid volume: 4,449 rows pulled for this drug, 3,717 (84%) suppressed by CMS for small cells and left out, never counted as zero, so every bar is a floor; state XX national rows excluded; the hatched latest quarter is preliminary. Fills also move with Medicaid enrollment, so a change is not by itself evidence of a shortage.

How long do shortages last?

Each step is a drop in the share of FDA shortage listings still running. The dot is this drug.

Share of FDA shortage listings still running after N months, with this drug marked0%25%50%75%100%024487296120months on the FDA listmedian 21 monthsthis listing (ended): 22 mo46% lasted this long
Kaplan-Meier on 397 listings, 2014 to 2026, by ingredient. 18 months have no capture and are bridged by inference. Every listing behind this curve, with the method and a dated correction, is in the shortage length dataset.

What a pharmacy pays per unit

NADAC is the average price retail pharmacies pay, per tablet.

Pharmacy acquisition cost per unit, brand against genericTablet 10 mg$0.824Tablet 5 mg$0.556
Thirty generic 5 mg tablets is about $16.68 at this benchmark. It is acquisition cost, not a retail price.

Which forms are short

FDA listing by dosage form
FormListed nowMonths listedFDA records (2026-11-05)
tabletNo (last listed December 2021)22 (2 records)

Price by strength

Tablet: generic acquisition cost per tablet by strength
StrengthNow2021 medianFirst monthNow vs 2021HistoryNDCs
5 mg$0.556$0.901$0.9032014-05-38%4
10 mg$0.824n/a$1.142017-07n/a17-month gap in NADAC reporting3
Read the price with care. NADAC is a national survey average of retail pharmacy invoices. It is not a quote, not what any patient paid, and it excludes discounts and rebates. A flat or falling benchmark during a shortage means pharmacies' average invoice cost did not rise, not that every patient could find the drug at that price.
FDA caution. The FDA drug shortage list is updated as manufacturers report and should not be relied on for medical care. Ask a pharmacist or prescriber about supply.

Questions

Is Pindolol still in shortage?

The tablet is not on the FDA shortage list as of 2026-11-05. It was listed from March 2020 to December 2021. FDA says not to rely on the list for medical care; ask a pharmacist.

Did the shortage raise the pharmacy price?

Not in the benchmark. The NADAC survey average for a generic 5 mg tablet is $0.556 in November 2026, 38% below its 2021 median and 38% below May 2014. NADAC is a national average of retail pharmacy invoices, so it measures what pharmacies pay on average, not what any one patient was charged.

Did Medicaid fills fall during the shortage?

No. CMS State Drug Utilization Data shows 663 Medicaid-paid tablet prescriptions in Q4 2025, 88% more than in Q4 2021 (352). Those counts are a floor because CMS suppresses small cells, they cover Medicaid only and move with Medicaid enrollment, and they count prescriptions that were filled, not demand that went unmet. A change in fills is not by itself evidence of a shortage.

What does a pharmacy pay for 30 generic 5 mg tablets?

About $16.68 on the NADAC benchmark ($0.556 per tablet times 30). That is acquisition cost, not a retail price: it excludes dispensing fees, discounts and rebates.

If you are trying to pay for or find this drug

Run a pharmacy, discount card, telehealth or assistance service that helps people pay for medicines? Apply to be evaluated for a page like this one, or hold a disclosed featured slot. Inclusion is earned. A slot is labelled sponsored and never implies a medical endorsement. Building a product on this data? Licence the widget or the data feed.

Cite this page

Figures are calculated from U.S. federal sources (see Data terms below) and rebuilt from dated snapshots. Cite it as:

OmniRx, "Pindolol: FDA shortage, NADAC acquisition cost and Medicaid utilization", data as of November 2026. https://omnirx.org/drugs/pindolol

Embed this chart

Free with attribution: paste this where you want the chart. It sizes itself to its content. A small "Powered by OmniRx" link stays in the widget; white-label licences remove it and add your own branding.

<iframe id="lx-drug-pindolol" src="https://omnirx.org/embed/drug-pindolol" width="100%" height="640" style="border:1px solid #e2e8f0;border-radius:10px" title="Pindolol shortage and price timeline by omnirx.org" loading="lazy"></iframe>
<script>addEventListener('message',function(e){if(e.origin!=='https://omnirx.org')return;var d=e.data||{};if(d.type==='lx-height'&&d.slug==='drug-pindolol'){var f=document.getElementById('lx-'+d.slug);if(f)f.height=d.height;}});</script>

Sources

Data terms. Every source above is published by a U.S. federal agency (CMS or FDA). CMS's data site labels its datasets inconsistently: of the 14 NADAC years, 5 carry the "public domain" label and 9 the "U.S. government works" label; of the 14 State Drug Utilization Data years, 6 carry the "public domain" label and 8 the "U.S. government works" label. We record each dataset's label verbatim and cite the source for every figure. Figures on this page are OmniRx calculations from those datasets, not statements by CMS or FDA, and no agency endorses this page.